2 unchanged sentences
Dexcom’s common stock is traded on the Nasdaq Global Select Market under the symbol “DXCM.”
−Removed: We had approximately 30 stockholders of record as of February 7, 2020 .
+Added: We had fewer than 40 stockholders of record as of December 31, 2020.
The number of beneficial owners of our common stock at that date was substantially greater than the number of record holders because a large portion of our common stock is held of record through brokerage firms in “street name.”
5 unchanged sentences
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
−Removed: Neither we nor any affiliated purchaser repurchased any of our equity securities in fiscal year 2019.
+Added: Neither we nor any affiliated purchaser repurchased any of our equity securities during the year ended December 31, 2020.
Company Stock Price Performance
−Removed: The graph below compares the cumulative total stockholder return on our common stock with the cumulative total returns on the Nasdaq Composite Index and the Nasdaq Medical Equipment Index over the five-year period ending December 31, 2019 .
+Added: The graph below compares the cumulative total stockholder return on our common stock with the cumulative total returns on the Nasdaq Composite Index and the Nasdaq Medical Equipment Index over the five-year period ended December 31, 2020.
The graph assumes that $100 was invested in Dexcom common stock and in each of the other indices on December 31, 2015 and that all dividends were reinvested.
2 unchanged sentences
* $100 invested on December 31, 2015 in stock or index, including reinvestment of any dividends.
−Removed: December 31, 2014
−Removed: December 31, 2015
−Removed: December 31, 2016
−Removed: December 31, 2017
−Removed: December 31, 2018
−Removed: December 31, 2019
+Added: December 31, 2015 December 31, 2016 December 31, 2017 December 31, 2018 December 31, 2019 December 31, 2020
+Added: $ 100.00 $ 72.89 $ 70.07 $ 146.28 $ 267.08 $ 451.43
Nasdaq Composite $ 100.00 $ 108.87 $ 141.13 $ 137.12 $ 187.44 $ 271.64
1 unchanged sentence
ITEM 6 - SELECTED FINANCIAL DATA
−Removed: The consolidated statements of operations data for the years ended December 31, 2019 , 2018 , and 2017 and the consolidated balance sheet data as of December 31, 2019 and 2018 have been derived from our audited consolidated financial statements included elsewhere in this Annual Report.
−Removed: The statements of operations data for the years ended December 31, 2016 and 2015 and the consolidated balance sheet data as of December 31, 2017 , 2016 and 2015 have been derived from our audited consolidated financial statements not included in this Annual Report.
−Removed: The following selected financial data should be read in conjunction with our “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 and our consolidated financial statements and related notes in Part II, Item 8 of this Annual Report.
−Removed: Twelve Months Ended
−Removed: (In millions, except per share data)
−Removed: Consolidated Statements of Operations Data:
−Removed: Product revenue
−Removed: Development grant and other revenue
−Removed: Total revenue
−Removed: Cost of sales
−Removed: Operating expenses:
−Removed: Research and development
−Removed: Collaborative research and development fees (1)
−Removed: Selling, general and administrative
−Removed: Total operating expenses
−Removed: Operating income (loss)
−Removed: Interest expense
−Removed: Income (loss) from equity investments
−Removed: Interest and other income (expense), net
−Removed: Income (loss) before income taxes
−Removed: Income tax expense
−Removed: Net income (loss)
−Removed: Basic net income (loss) per share (2)
−Removed: Shares used to compute basic net income (loss) per share (2)
−Removed: Diluted net income (loss) per share (2)
−Removed: Shares used to compute diluted net income (loss) per share (2)
−Removed: As of December 31,
−Removed: (In millions)
−Removed: Consolidated Balance Sheet Data:
−Removed: Cash, cash equivalents, and short-term marketable securities
−Removed: Working capital
−Removed: Long-term liabilities
−Removed: Total stockholders’ equity
−Removed: See Note 2 to the consolidated financial statements in Part II, Item 8 of this Annual Report for a description of our Restated Collaboration Agreement with Verily Life Sciences LLC and Verily Ireland Limited.
−Removed: See Note 1 to the consolidated financial statements in Part II, Item 8 of this Annual Report for a description of the method used to compute basic and diluted net loss per share attributable to common stockholders.
+Added: Omitted pursuant to amendments to Item 301 of Regulation S-K effective February 10, 2021.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.